Evidence map›Paper›PMID 28612085›Full record

ArticleAnalytical and bioanalytical chemistry2017

Moving from millifluidic to truly microfluidic sub-100-μm cross-section 3D printed devices.

Michael J Beauchamp, Gregory P Nordin, Adam T Woolley

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Cleanroom-Free Fabrication of Microneedles for Multimodal Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2023
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael J BeauchampDepartment of Chemistry and Biochemistry, Brigham Young University, C100 BNSN, Provo, UT, 84602, USA.
Gregory P NordinDepartment of Electrical and Computer Engineering, Brigham Young University, Provo, UT, 84602, USA.
Adam T WoolleyDepartment of Chemistry and Biochemistry, Brigham Young University, C100 BNSN, Provo, UT, 84602, USA. atw@byu.edu.

Funding

Phase-Changing Sacrificial Layer Microfluidics for Enhanced Protein AnalysisR01EB006124 · NIBIB · BRIGHAM YOUNG UNIVERSITY · PI WOOLLEY, ADAM THOMAS · 2006 to 2016
$3.1M
NIBIB NIH HHS R01 EB006124
6 · The paper itself

Abstract

Three-dimensional (3D) printing has generated considerable excitement in recent years regarding the extensive possibilities of this enabling technology. One area in which 3D printing has potential, not only for positive impact but also for substantial improvement, is microfluidics. To date many researchers have used 3D printers to make fluidic channels directed at point-of-care or lab-on-a-chip applications. Here, we look critically at the cross-sectional sizes of these 3D printed fluidic structures, classifying them as millifluidic (larger than 1 mm), sub-millifluidic (0.5-1.0 mm), large microfluidic (100-500 μm), or truly microfluidic (smaller than 100 μm). Additionally, we provide our prognosis for making 10-100-μm cross-section microfluidic features with custom-formulated resins and stereolithographic printers. Such 3D printed microfluidic devices for bioanalysis will accelerate research through designs that can be easily created and modified, allowing improved assays to be developed.

Indexed as

Lab-On-A-Chip DevicesPrinting, Three-DimensionalPoint-of-Care SystemsBioanalytical methodsMicrofluidics/microfabricationSeparations/instrumentation

Identifiers

PMID28612085
PMCPMC5542000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.